Overview
Asiri Surgical Hospital operates a 155-plus-bed private surgical hospital, with more than 200,000 channellings and over 8,800 surgeries across routine and complex disciplines.
The latest quarter showed improving earnings momentum, with profit growing faster than revenue. However, the annual return on owners' equity remains modest, so the central question is whether stronger operating performance can translate into better shareholder returns.
Price performance
AMSL closed at LKR 15.00 on 17 August 2026. Over three months it fell 35.3%, substantially worse than the ASPI's 5.6% decline; over one year it gained 11.1%, slightly ahead of the index's 9.6% return.
The stock sits at 13.1% of its 52-week range, close to the lower end. Sixty-day annualised volatility was 49.5%, 20.7% below its own one-year level, while recent volume was below its 60-day norm. The price data show weak recent performance, but do not establish why the market moved.
Valuation
AMSL trades on a P/E of 9.35 and a P/B of 1.07, against healthcare peer medians of 19.88 and 2.37 respectively. The discount is substantial, but annual ROE was only 4.1%, which provides limited support for a premium book valuation. A sector percentile is not supplied, so the exact ranking within healthcare cannot be established.
No dividend yield is shown. The recorded payout was LKR 0.30 per share for FY2025, compared with LKR 2.10 in FY2022; the recent payout is therefore materially lower, although the latest financial year may not yet be complete in the dividend record.
News and sentiment
Coverage was normal, with two material articles in the 90-day window, split between one positive and one negative item. The negative flow included CSE enforcement-action notices and a report that a tax dispute involving Asiri Surgical remains under appeal within Softlogic Holdings' disclosures.
The recorded LKR 0.30 first interim dividend had an ex-date of 26 September 2024 and payment date of 15 October 2024. No undated corporate action is currently recorded.
Financials
For the June 2026 quarter, revenue grew 7.4% year-on-year and net profit grew 11.6% to LKR 226 million. Gross margin was unchanged at 43.2% against the comparable June quarter, while net margin improved from 10.7% to 11.1%. Gross margin ranked 2nd of 6 comparable June quarters, whereas net margin ranked 4th of 6, so the improvement in earnings was positive but not historically exceptional on the bottom line.
The latest filing reports group revenue of LKR 2.04 billion and group equity of LKR 8.00 billion, with 528 million shares outstanding. The share count has been unchanged across the latest comparable quarters, so the profit improvement is not a mechanical per-share effect. Operating profit was not disclosed for the June quarter, preventing a precise separation of operating improvement from finance costs, tax and other below-the-line items.
The twelve months to June 2026 generated revenue of LKR 7.86 billion, up 6.6%. The latest audited year ended March 2025 showed ROE of 4.1% and net profit down 49.9%, so the recent quarterly recovery is being measured against a weaker earlier earnings base rather than against consistently high returns.
Risks
The most important risk is cash generation. In the latest audited year, cash conversion was negative at -0.18 times and free cash flow was negative LKR 435 million, meaning reported operating profit did not arrive as cash after investment requirements.
Financing remains a constraint despite lower debt: gearing was 37.1% of owners' equity and interest cover was only 1.97 times at March 2025. The current ratio was 1.25, leaving less liquidity headroom than the prior year's 1.47. In addition, 28.9% of group profit belonged to minority shareholders, so group net profit and the earnings attributable to AMSL shareholders are not the same pool of money.
The broader backdrop is mixed. Falling Sri Lankan interest rates could reduce financing pressure across the sector, but elevated energy and transport costs remain an industry-wide cost risk. Healthcare operators also face stronger cybersecurity expectations, while the reported tax appeal creates company-specific uncertainty.
Outlook
The next material event is the September 2026 quarter filing. As at 17 August 2026, it is expected between 7 November 2026 and 7 January 2027, and it will supersede the June-quarter figures used here. That filing will show whether the recent profit growth is accompanied by operating-profit disclosure and stronger cash conversion.
Lower domestic interest rates may ease finance pressure across the healthcare sector, but the available data cannot determine the effect on Asiri Surgical specifically. The tax appeal also has no dated outcome in the supplied information, so its financial effect cannot be assessed beyond the uncertainty already disclosed.